vimarsana.com

Page 252 - Advanced Cellular Technology News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Novo Nordisk Aims to Succeed Where Sanofi Faltered Drugging a Weight-Loss Target

Novo Nordisk isn’t putting all of its weight loss drug hopes in the same basket. Its acquisition of Inversago Pharma for up to $1 billion will bring a biotech whose lead drug candidate has early clinical trial data showing significant weight loss.

Suvida Healthcare Taps Elation EHR to Help Power Care for Hispanic Seniors

Suvida Healthcare a startup providing primary care for Medicare-eligible Hispanic adults is adopting Elation Health’s primary care-specific technology platform. The platform comprises an EHR, as well as software for patient engagement, telehealth and revenue cycle management. Suvida's chief medical officer said Elation beat out the competition due to its focus on both primary care and value-based care.

Why Amazon Is Expanding Its Family Building Benefits Globally Through Maven Clinic

Amazon selected Maven Clinic to provide fertility and family building support to its global employees across 50 countries. This includes support from care advocates and unlimited access to its virtual specialists like OB/GYNs and reproductive endocrinologists.

Survey: Only 44% of MA Beneficiaries Fully Understand Their Plan

Only 44% of Medicare Advantage enrollees said they “fully understand” their plan, while 50% said they “somewhat understand” it and 6% said they don’t understand it, according to a recent survey.

Healthcare M&A Activity Reaches 3-Year Low, But It Might Pick Up in the Back Half of 23

M&A activity in the healthcare sector continued to decline in the second quarter of 2023, with the number of deals reaching its lowest point in three years. However, a new report predicted that M&A activity could increase in the second half of this year due to healthcare companies’ continually shrinking valuations and their divestitures of non-core assets.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.